Despite viral claims, no randomized head-to-head study of Dysport vs Botox for frown lines exists as of May 2026. The genuine Dysport vs Botox study, the DIRECTION trial, compared the two for upper-limb spasticity, not aesthetics. Separately, SCALE 2026 showed Ipsen's new corabotase versus Dysport for glabellar lines.
- No randomized Dysport vs Botox head-to-head for frown lines has been published as of May 2026.
- The real Dysport vs Botox study (DIRECTION, Phase IV, 464 adults) compared them for upper-limb spasticity, not wrinkles.
- In DIRECTION, Dysport showed comparable safety and a modestly longer duration (about 14.2 vs 13.8 weeks).
- At SCALE 2026, Ipsen presented corabotase, a new recombinant toxin, versus Dysport for glabellar lines, not Dysport vs Botox.
- For frown lines, no toxin is crowned the winner; the injector's skill matters more than the brand.
Patients and providers constantly debate which toxin is better, yet rigorous direct comparisons have been surprisingly rare.
May brought a notable step toward an evidence-based answer.
What actually happened
Two separate May 2026 developments were widely conflated into a single, non-existent claim: a randomized Dysport versus Botox comparison for frown lines. No such published head-to-head exists. Ipsen did announce, on May 19, 2026, late-breaking data from the DIRECTION trial, described as the first head-to-head study comparing Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA). But DIRECTION is a Phase IV crossover trial in 464 adults with upper-limb spasticity, a therapeutic rather than cosmetic use. It reported comparable safety (roughly 20.3 percent versus 23.0 percent adverse events) and a modestly longer duration for Dysport (about 14.2 versus 13.8 weeks).
Separately, at the SCALE 2026 symposium, Ipsen presented Phase II data for corabotase, a new first-in-class recombinant neurotoxin, against Dysport and placebo for glabellar (frown) lines. That study compares a new drug with Dysport, not Dysport with Botox. The two events share a sponsor and a month, which is how they became merged into a headline that reflects neither study accurately.
Why it matters
For anyone deciding between Dysport and Botox for frown lines, the honest answer is that no randomized, controlled head-to-head has settled the question. Both are FDA-approved for glabellar lines, and both have long safety records when injected by a qualified, licensed provider. Claims that one brand definitively beats the other for wrinkles are not supported by a direct aesthetic trial. Where products are genuinely similar, the injector's assessment, dosing, and technique matter more than the label on the vial.
What to watch
Watch for peer-reviewed publication of the DIRECTION spasticity data, and for whether any sponsor runs a true aesthetic Dysport versus Botox head-to-head for frown lines. Corabotase, still investigational and not FDA-approved, is worth tracking as a potential longer-duration option if it advances. For patients, the steady guidance is unchanged: choose an experienced injector and an FDA-approved toxin suited to your goal, and treat single-conference headlines, especially brand-versus-brand ones, with caution.
Frequently asked questions
Is there a real study comparing Dysport and Botox?
So which is better for frown lines, Dysport or Botox?
What was actually shown at SCALE 2026?
Is corabotase available?
- 1.Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines — Ipsen (2026-05-16)
- 2.Ipsen announces late-breaking data from first head-to-head study comparing Dysport and Botox in adults with upper limb spasticity — Ipsen (via GlobeNewswire) (2026-05-19)
- 3.Dysport Demonstrates Comparable Safety, Longer Duration Than Botox in Phase 4 Upper Limb Spasticity Trial — NeurologyLive (2026-05-19)
- 4.Ipsen: sustained duration of effect in corabotase trial — Clinical Trials Arena (2026-05-18)